Aytu BioPharma, Inc. (AYTU) Stock Forecast
AYTU analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $9.67 average of analyst targets
- Upside to target
- +373.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.10
- 52-week range
- $1.94 – $2.90
AYTU analyst ratings
3 analystsNumber of analysts at each rating.
AYTU price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AYTU earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.26 | −$0.10 | −$0.09 | −92.7% | 2 |
| Next quarter (Dec '26) | −$0.14 | −$0.18 | −$0.09 | −$0.23 | +42.1% | 2 |
| Current fiscal year (FY2027) | −$0.36 | −$0.57 | −$0.16 | −$0.83 | +56.0% | 2 |
| Next fiscal year (FY2028) | $0.15 | $0.14 | $0.17 | −$0.36 | +142.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AYTU revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $13.3M | $12.3M | $14.5M | −4.4% | 3 |
| Next quarter (Dec '26) | $15.3M | $15.0M | $15.7M | +0.8% | 3 |
| Current fiscal year (FY2027) | $67.9M | $67.4M | $68.3M | +18.0% | 3 |
| Next fiscal year (FY2028) | $86.9M | $76.0M | $94.1M | +28.0% | 3 |
AYTU EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AYTU revenue: reported and forecast
AYTU EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.02 | −$0.02 | −$0.02 | −$0.02 | −$0.18 | +800.0% | 0 up · 1 down |
| Next quarter (Dec '26) | $0.02 | $0.02 | $0.02 | $0.02 | −$0.14 | −775.0% | 0 up · 1 down |
| Current fiscal year (FY2027) | −$0.07 | −$0.07 | −$0.07 | −$0.07 | −$0.36 | +386.7% | 0 up · 2 down |
| Next fiscal year (FY2028) | $0.00 | $0.00 | $0.00 | $0.00 | $0.15 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AYTU earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AYTU beat in 9 of 12.
What analysts expect from AYTU
3 analysts cover Aytu BioPharma; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.67, 373.9% above the latest close of $2.04. Analysts expect earnings of −$0.36 per share for FY2027, +56.0% from a year earlier. For FY2028 the average estimate is $0.15 per share on revenue of $86.9 million. Aytu BioPharma beat the EPS estimate in 9 of the last 12 quarters.
Related: AYTU income statement, AYTU key metrics, AYTU chart. See the AYTU stock overview for the latest quote and news.
AYTU forecast FAQ
What is Aytu BioPharma's price target?
The average analyst price target for Aytu BioPharma is $9.67, 373.9% above the latest close of $2.04.
Is Aytu BioPharma a buy, hold or sell?
Of 3 analysts covering Aytu BioPharma, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aytu BioPharma's EPS forecast?
Analysts forecast −$0.36 per share for FY2027 (range −$0.57 to −$0.16); for FY2028 the estimate is $0.15.
What is Aytu BioPharma's revenue forecast?
The average revenue estimate for FY2027 is $67.9 million, growth of 18.0%; for FY2028 it is $86.9 million.
When does Aytu BioPharma report earnings?
Aytu BioPharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.10.
Does Aytu BioPharma usually beat earnings estimates?
Aytu BioPharma reported EPS at or above the analyst estimate in 9 of the last 12 quarters.